Get the Stockscreener App
1.855
6.15%
-0.095
Veraxa Biotech Ag stock is traded at $1.855, with a volume of 222.59K.
It is down -6.15% in the last 24 hours and up +1.67% over the past month.
Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
See More
Previous Close:
$1.95
Open:
$1.98
24h Volume:
222.59K
Relative Volume:
0.52
Market Cap:
$255.95M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-1.61%
1M Performance:
+1.67%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.81
$2.00
1-Week Range:
$1.76
$2.00
52-Week Range:
$1.70
$26.01
Veraxa Biotech Ag Stock (VRXA) Company Profile
Compare VRXA vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VRXA
Veraxa Biotech Ag
|
1.81 | 267.26M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
548.18 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
826.66 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,010.79 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
139.66 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.77 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Veraxa Biotech Ag Stock (VRXA) Latest News
VERAXA Biotech AG: Valuation Ratios, Analysts' Forecasts - marketscreener.com
Veraxa Biotech (VRXA) interim CFO discloses zero share ownership - Stock Titan
VERAXA Biotech Leverages AI to Advance Precision Oncology Pipeline - citybuzz -
VERAXA Biotech Leverages AI to Enhance Precision Oncology Pipeline - citybuzz -
Dividend HistoryVeraxa Biotech AG (VRXA) - Zacks Investment Research
VRXA: Veraxa Biotech AGInsider Transations - Zacks Investment Research
VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - USA Today
AQR group (VRXA) discloses 658,138-share Veraxa Biotech position under 5% threshold - Stock Titan
Veraxa Biotech AG Ord Shs (VRXA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Veraxa Biotech Holding AG SEC Filing (Aug 10, 2026) - Stock Titan
VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer - USA Today
VERAXA Biotech Advances Antibody Therapeutics with Innovative BiTAC Platform - citybuzz -
Veraxa Biotech Holding AG SEC Filing (Aug 7, 2026) - Stock Titan
VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-G - Benzinga
VERAXA Biotech Advances VXA-222 Cancer Program and Expands Patent Portfolio - citybuzz.co
VERAXA Biotech (NASDAQ: VRXA) Receives Regulatory Feedback for BiTAC-TCE Cancer Therapy Platform - USA Today
Veraxa Biotech (VRXA) grows patent estate for BiTAC cancer platforms - Stock Titan
Veraxa Biotech files first BiTAC patent applications in 2026 By Investing.com - Investing.com Canada
VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates - The Manila Times
VERAXA Biotech (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures - Benzinga
Veraxa Biotech AG Ord Shs (VRXA) Institutional Confidence - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Veraxa Biotech (VRXA) moves bispecific ADC VXA-222 program forward - Stock Titan
VERAXA Biotech (VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration - NewMediaWire
Veraxa advances cancer therapy program with OmniAb By Investing.com - Investing.com South Africa
Veraxa Biotech AG Ord Shs (VRXA) Cash Flow - TradingKey
Veraxa Advances Bispecific ADC Candidate VXA-222 Following OmniAb Discovery Milestone - BioPharm International
VERAXA Biotech Advances Bispecific ADC Program VXA-222 Under OmniAb Collaboration - citybuzz -
VERAXA Biotech Shareholders Overwhelmingly Approve Corporate Governance and Financing Measures - citybuzz -
Veraxa Biotech AG Ord Shs (VRXA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Veraxa Biotech advances bispecific ADC from Omniab collaboration - BioWorld News
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb - The Manila Times
VERAXA Biotech Announces Advancement of VXA-222 Bispecific ADC Program in Collaboration with OmniAb - Quiver Quantitative
VERAXA’s VXA-222 Uses One Molecule to Address Two Tumor Antigens - Stock Titan
Veraxa Biotech AG Ord Shs (VRXA) Balance Sheet - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
VRXA|Veraxa Biotech AG Ord Shs|Price:1.800|Chg%:-0.060 - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Veraxa Biotech AG Ord Shs (VRXA) Income Statement - TradingKey
Veraxa Biotech shareholders approve governance changes By Investing.com - Investing.com India
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth - The Manila Times
VERAXA Biotech AG (VRXA) Appoints Christoph Erkel as Chief Scientific Officer - NewMediaWire
Veraxa Biotech AG Revenue Breakdown – FWB:J8L0 - TradingView
VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel As Chief Scientific Officer - Menafn
VERAXA Biotech (VRXA) Advances BiTAC(R)-TCE Development With Positive Regulatory Feedback From Germany - Yahoo Finance
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Lead BiTAC Platform Development - citybuzz -
VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC® Technology Platforms and Portfolio - The Manila Times
Veraxa Biotech names Christoph Erkel as chief scientific officer By Investing.com - Investing.com UK
Veraxa Biotech Ag Stock (VRXA) Financials Data
There is no financial data for Veraxa Biotech Ag (VRXA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.35%
0.62%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):